Proactive Investors - Run By Investors For Investors

BARD1 Life Sciences Ltd raising funds for novel cancer diagnostics

The company is developing diagnostic tests for early detection of cancer.
BARD1 Life Sciences Ltd raising funds for novel cancer diagnostics
The technology is based on BARD1, a potent tumour suppressor

BARD1 Life Sciences Ltd (ASX:BD1) has received binding commitments to raise $1,097,325 via the issue of shares to sophisticated and professional investors at an issue price of $0.008 per share.

The company will also conduct a share purchase plan (SPP) for eligible shareholders to raise up to a further $1 million at the same issue price.

Funds raised from the placement and SPP will be used to fund ongoing research and development programs, commercial initiatives and for general working capital purposes.

BARD1 is an Australian life sciences company developing novel diagnostics and therapeutics for unmet needs in cancer.

The company’s proprietary BARD1 Technology is based on BARD1, a potent tumour suppressor in healthy individuals and an important tumour biomarker in cancer.

BARD1’s lead product, the BARD1 Lung Cancer Test, is a non-invasive blood test in development for early detection of lung cancer.

The company is also researching a high-value pipeline of potential diagnostic and therapeutic products for multiple cancers.

BARD1’s research activities are currently performed under a research contract at the University of Geneva (UNIGE).

The company’s business strategy is to focus on leveraging its BARD1 Technology to develop diagnostic tests for early detection of cancer where there are clear unmet needs and product advantages.

View full BD1 profile View Profile

Bard1 Life Sciences Ltd Timeline

Related Articles

June 27 2018
Lancor Scientific is aiming to carry out an initial coin offering by issuing Medici, a new currency based on Ethereum to help Tumour Trace to fund further development
February 22 2019
Motif’s lead drug candidate is iclaprim, a next-generation antibiotic for which it was seeking US FDA approval for use in patients with acute bacterial skin and skin structure infections
scientist in lab
February 26 2019
Results from a 62-patient follow-up study are due shortly, while data from a 500-person-strong managed access programme should be available by the end of next year

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use